DATA & TOOLS
DATA & TOOLS: What is your favorite biotech stock worth when it’s time for a Big Pharma license deal?
This biotech model generates risk-adjusted values broken down on both licensor and licensee. 💊💉🔬🧬🧪
Latest
COMMISSIONED EQUITY RESEARCH
NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential
Read More Read Less
COMMISSIONED EQUITY RESEARCH
GRANGEX: Striking renegotiation of Sydvaranger acquisition setting GRANGEX up for an eventful 2024
Read More Read Less
SHORTS & FRAUDS
New addition to Shorts & Frauds list: Management walkout in $3.1B cloud infrastructure continues as retention declines
Despite strong industry tailwinds, key executives continue to jump ship as declining retention rates persist. Addressing this will likely require significant investment. Coupled with modest ARPU and slowing ARR growth, this warrants a soft sell approach.
COMMISSIONED EQUITY RESEARCH
CRUNCHFISH: Broadening of scope to all offline credentials
Read More Read Less
RESEARCH
Reddit set to catch up to tech giants
While a small niche player in social media and not yet profitable, Reddit boasts a unique platform, high gross margins, outsized growth among high-value US users, and a strong focus on improved monetization. These factors should drive a closing of the gap to peers.
RESEARCH
Utilities have led SPX in the past month, here's why insiders are piling in: Highlights from the first 3 reports of top 15 giants
In the past month, the Utilities sector (XLU) have outperformed the SPX by nearly 8ppt. Now, three of the top 15 companies have reported for Q1, showing that the Utilities sector are at a crossroads.
RESEARCH
Evidence is mounting of a Chinese devaluation - Here are two ways to play it
While there is mounting evidence pointing to an imminent devaluation of the Chinese CNY, it is surprisingly hard to get exposure to such an event after the ETF CYB was discontinued in 2023. Here are two ways to play it.
COMMISSIONED EQUITY RESEARCH
PROLIGHT: Important milestone amidst mixed news flow
Read More Read Less
SHORTS & FRAUDS
List of potential Shorts and Frauds
Essential to long-term success is avoiding the meltdowns. Here we list potential shorts and frauds, and their key issues. Feel free to hit me up with your best short idea and maybe we'll add it to the list. We update this list continuously.
OSINT
This week in OSINT for investors
This week, we note NatGas contango, oil backwardation softening, early reporting season EPS surprise and the Middle East holding its breath in anticipation of Israel's response.
COMMISSIONED EQUITY RESEARCH
CRUNCHFISH: Major TAM expansion with broadening to secure and scalable mobile card payments
Read More Read Less
SECTORS & THEMES
Two ETFs to play a commodity-driven reflation
With equities taking a breather, commodities are picking up steam, led by Crude, Copper and the whole Agri spectrum. This is likely to drive a rebound in inflation. Here are two ways to play it.
COMMISSIONED EQUITY RESEARCH
PROLIGHT: PoC troponin testing ready for next step
Read More Read Less
COMMISSIONED EQUITY RESEARCH
NANEXA: Focus on dual GLP-1 opportunities and the partner projects
Read More Read Less
COMMISSIONED EQUITY RESEARCH
GRANGEX: Starting to fuel up: GRANGEX set for busy agenda in 2024
Read More Read Less